On December 22, 2021, Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn's disease and ulcerative colitis, announced the company has closed on a $31 million Series A financing. The round was co-led by New Enterprise Associates (NEA) and Arix Bioscience plc. The new funding will be used to advance its pipeline of novel oral antibodies to address unmet needs in immune-mediated diseases.
Wilson Sonsini Goodrich & Rosati advises Sorisso on patent matters, including those related to this transaction. The team representing Sorriso in this transaction is led by Matt Wheeler and includes Brett Zirkle and Mike Hostetler.
For more information, please see Sorriso's press release.